Mesoblast expands operational management to prepare rexlemestrocel-L for commercial scale-up
Mesoblast Limited (ASX:MSB; Nasdaq:MESO) is expanding its operational management to augment commercial preparedness for its second-generation product, rexlemestrocel-L, in inflammatory chronic low back pain (CLBP) and cardiovascular diseases. Both indications have completed Phase 3 programs and are in line for important readouts and U.S. Food and Drug Administration (FDA) filings.
The move follows what the company describes as growing revenues from Ryoncil® (remestemcel-L-rknd), its first FDA-approved product. Chief Executive Dr. Silviu Itescu framed the platform’s role in broader terms.
Ryoncil revenue growth of 44% to US$28 million in the latest quarter, alongside a sharp fall in net cash spend, shows the commercial base funding this next stage.
Dr. Silviu Itescu, Chief Executive
“…This platform becomes the engine for scientific innovation, revenue growth and shareholder value.”
When big ASX news breaks, our subscribers know first
Interim COO appointed to lead CLBP commercial preparation
Why the CLBP readout matters
A successful outcome of the CLBP Phase 3 trial readout during the second half of calendar 2027 will underpin “one of the most valuable commercial opportunities” in the Mesoblast portfolio. As a result, a primary corporate objective is to prepare for commercial manufacturing scale-up and potential commercial launch activities for the CLBP product.
Who is stepping in
Dr. Gregory George will act as interim Chief Operating Officer (COO) while the company searches for a full-time COO. He founded and managed the largest privately owned ambulatory surgical center company in the United States, SurgCenter Development, and is a Mesoblast Director.
Dr. Gregory George
“…My immediate focus will be on driving operational efficiencies, accelerating the commercialization of our innovative cell therapies, and building a scalable, profitable business that delivers long-term value to patients and shareholders.”
Key employment terms
The material terms of the interim COO employment agreement, disclosed under ASX Listing Rule 3.16.4, are:
- A full-time agreement ending on the earlier of six months from commencement and the commencement of a permanent COO, unless extended by agreement.
- Either Mesoblast or Dr. George may terminate the agreement at any time.
- The role reports to the Chief Executive.
- Total fixed remuneration of US$500,000 per annum.
- Eligibility to participate in Mesoblast’s employee share option plan as a component of remuneration. To the extent required under the ASX Listing Rules, any options granted will require prior shareholder approval.
Cardiovascular pathway and CMO transition
FDA alignment on heart failure filing
Mesoblast recently met with the FDA and obtained alignment on filing a Biologics License Application for rexlemestrocel-L. The application would target a reduction in life-threatening major gastrointestinal bleeding in end-stage heart failure patients being kept alive by a left ventricular assist device (LVAD).
Label expansion strategy
Mesoblast’s strategy for entering the cardiovascular market has two parts:
- Obtain approval in end-stage heart failure patients with an LVAD.
- Then expand the label to moderate/severe heart failure, including the new opportunity in patients with life-threatening pulmonary hypertension.
The common thread between these patient populations is severe inflammation and endothelial dysfunction, which affects the arteries in the heart, the lungs and the gastrointestinal tract.
Dr. Eric Rose steps into a focused CMO role
Dr. Eric Rose will focus his efforts as Chief Medical Officer on the opportunities for rexlemestrocel-L in the company’s cardiopulmonary franchise. He will step away from the Board.
The company describes Dr. Rose as a world-renowned heart surgeon and scientist who performed the world’s first successful pediatric heart transplant. As Chairman of Columbia University’s Department of Surgery, his scientific leadership resulted in the first FDA approval of an implantable LVAD for long term circulatory support.
What this means for investors
The announcement adds management capacity ahead of two late-stage milestones: the CLBP Phase 3 readout and the planned Biologics License Application in LVAD patients. Both sit within the rexlemestrocel-L program that the company is positioning for commercial scale-up.
Mesoblast develops allogeneic cell therapies, which are “off-the-shelf” medicines made from donor cells rather than from each patient’s own cells. Manufacturing scale-up matters ahead of a potential launch because a product needs to be produced in sufficient volume to supply patients if it is approved.
Scale-up credibility already has a precedent in the FDA’s potency assay approval for Ryoncil, which allows commercial batch release as production moves to new facilities.
The company also states that it holds over 1,000 granted patents or patent applications, providing commercial protection extending through to at least 2044 in all major markets.
What happens next for Mesoblast
- CLBP Phase 3 trial readout: expected during the second half of calendar 2027, with a successful outcome underpinning the CLBP commercial opportunity.
- Full-time COO search: underway by the company. The interim COO term ends on the earlier of six months from commencement and the start of a permanent COO, unless extended by agreement.
- Biologics License Application for rexlemestrocel-L in LVAD patients: FDA alignment has been obtained on the filing.
Get Healthcare News Before the Market Moves
Get FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already using Big News Blast to stay ahead of the market. Click the “Free Alerts” button to start receiving alerts the moment market-moving news breaks.